title: [Hormone replacement therapy in women with arterial hypertension in peri- and postmenopause: hemodynamic effects].
abstract: OBJECTIVE
  To study hemodynamic effects of replacement hormone therapy (RHT) with trisecvens, beta-blocker betaksolol and their combination in perimenopausal and menopausal women with hypertension.
  
  
  METHODS
  The study was made of 60 menopausal women aged 45-60 with mild and moderate arterial hypertension (AH). The women had no contraindications to either RHT or beta-blockers. They were randomized into three groups: group 1 received trisekvens, group 2--trisekvens plus betaksolol in a dose 10-20 mg/day, group 3--betaksolol. Arterial pressure (AP) and heart rate (HR) were measured before the treatment, in one month and each three months for a year. ECG and echo-CG were registered before treatment and each 3 months of the therapy. AP monitoring covered 50% of the patients of each group before the treatment and after 1 and 3 months of it. The data were analysed according to SAS system.
  
  
  RESULTS
  Group 1 patients showed no significant changes in AP and HR. Group 2 and 3 patients' AP lowered, in group 2 the fall of systolic AP being more pronounced. 12-month therapy brought about a 10.3% decrease in left ventricular myocardial mass index in group 2.
  
  
  CONCLUSIONS
  RHT with trisekvens in combination with beta-blocker in long-term use potentiates the effect on systolic AP and reduced hypertrophy of the left ventricle. RHT does not produce a significant effect on AP in women with AH recorded before the menopause.
authors.forename: M M
authors.initials: MM
authors.lastname: Bystrova
authors.forename: A N
authors.initials: AN
authors.lastname: Britov
authors.forename: V M
authors.initials: VM
authors.lastname: Gorbunov
authors.forename: A V
authors.initials: AV
authors.lastname: Lebedev
authors.forename: N A
authors.initials: NA
authors.lastname: Eliseeva
authors.forename: V P
authors.initials: VP
authors.lastname: Smetnik
authors.forename: O P
authors.initials: OP
authors.lastname: Slasten
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D015784:Betaxolol / Q000627:therapeutic use*; D002979:Climacteric; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D004958:Estradiol / Q000627:therapeutic use*; D004964:Estriol / Q000627:therapeutic use*; D015914:Estrogen Replacement Therapy; D005260:Female; D006439:Hemodynamics; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D008875:Middle Aged; D009640:Norethindrone / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D017698:Postmenopause
chemical_list: D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D004338:Drug Combinations; D004958:Estradiol; C032040:Trisequens; D004964:Estriol; D015784:Betaxolol; D009640:Norethindrone
vernacular_title: Zamestitel'naia gormonoterapiia u zhenshchin s arterial'noĭ gipertonieĭ v peri- i postmenopauze: gemodinamicheskie éffekty.